Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Sunoco LP Stock Races Higher: What’s Going On?

Sunoco LP (NYSE: SUN) shares are racing higher and marked a new 52-week high price on Thursday. What To Know:
byErica Kollmann
September 28, 2023
1 minute read
Total
0
Shares
0
0
0
0
0
0

Sunoco LP (NYSE:SUN) shares are racing higher and marked a new 52-week high price on Thursday.

What To Know:

Sunoco LP shares reached a 52-week high of $51.85 as the price of crude oil continues its recent rally.

The price of crude oil climbed over $95 per barrel on Wednesday for the first time in over a year and is currently trading above $92 per barrel.

Sunoco shares are moving higher on heavy trading volume, and SUN is listed as one of the top trending tickers on Yahoo! Finance. 

According to data from Benzinga Pro, more than one million shares have been traded in the session, compared to the stock’s 100-day average of just over 154 thousand shares.

Related News: What’s Going On With Palantir Technologies Stock? 

SUN Price Action: According to Benzinga Pro, Sunoco LP shares are up 8.5% at $51.32 at the time of publication.

Image: Rudy and Peter Skitterians from Pixabay

 
Total
0
Shares
Share 0
Tweet 0
Share 0
Share 0
Share 0
Share 0
Related Posts
Read More

Asian Markets Mixed, Europe Trades Higher Influenced By ECB’s Signal Of Ending Rate Hike Cycle – Global Markets Today While US Was Sleeping

By Akanksha Bakshi
September 15, 7:40 AM
On Thursday, September 14, U.S. markets ended higher; the Dow surged over 300 points, its biggest single-day gain in over five weeks. The increase was driven by the strong performance of the U.S. consumer sector, supported by recent retail sales data.

ADIV

Read More

AbbVie Announced FDA Approved the Use of Imbruvica for the Treatment of Pediatric Patients One Year and Older With cGVHD After Failure of One or More Lines of Systemic Therapy

By Charles Gross
August 24, 7:26 PM
AbbVie (NYSE: ABBV) today announced that the U.S. Food and Drug Administration (FDA) approved the use of IMBRUVICA® (ibrutinib) for the treatment of pediatric patients one year and older with chronic graft versus host disease (cGVHD) after failure of one or more lines of systemic therapy.

ABBV